Escitalopram

Introduction Overview

Generic Name

escitalopram

Brand Name

Lexapro

Dosage Form

tablets, oral solution

Drug Class

Selective serotonin reuptake inhibitors (SSRIs)

Pharmacokinetics

Absorption:
Escitalopram is well absorbed after oral administration, with peak plasma concentrations reached approximately 4 to 6 hours after dosing. The oral bioavailability is high and not significantly affected by food intake, allowing for flexible administration with or without meals. This predictable absorption profile contributes to consistent therapeutic effects. Clinical studies demonstrate that the steady-state plasma concentrations are achieved within one week of daily dosing.

Distribution:
The drug is widely distributed throughout the body tissues and crosses the blood-brain barrier effectively, which enables its central nervous system activity. Escitalopram is approximately 56% bound to plasma proteins, which facilitates its distribution while maintaining pharmacologically active unbound concentrations. The apparent volume of distribution (Vd) ranges around 12-26 L/kg, indicating extensive tissue binding.

Metabolism:
Escitalopram undergoes extensive hepatic metabolism primarily via cytochrome P450 isoenzymes, notably CYP2C19, CYP3A4, and CYP2D6. It is metabolized to demethylated metabolites, which possess minimal pharmacologic activity. Genetic polymorphisms affecting CYP2C19 can influence plasma levels, resulting in varied metabolism rates among patients, which may require dose adjustments. Co-administration with CYP inhibitors or inducers may also alter drug metabolism, impacting efficacy and safety.

Elimination:
The elimination half-life of escitalopram is approximately 27 to 32 hours, allowing once-daily dosing. It is predominantly eliminated via renal excretion of metabolites, with less than 5% excreted unchanged in urine. Steady state concentrations are typically reached after one week of continuous dosing. In patients with renal or hepatic impairment, clearance may be reduced, necessitating careful monitoring and dose adjustments. The drug does not accumulate excessively, and elimination kinetics support a relatively predictable pharmacokinetic profile.

Overall, escitalopram’s pharmacokinetic properties favor its use as a once-daily oral antidepressant with a well-established safety and efficacy profile. Clinical considerations include adjustment in special populations and vigilance regarding drug interactions affecting metabolism.

Dosage Forms

Available Dosage Forms:
Lexapro is available as oral tablets and an oral solution formulation. The tablets come in strengths of 5 mg, 10 mg, and 20 mg, facilitating tailored dosing for initiation and maintenance therapy. The oral solution strength is 1 mg/mL, allowing for precise dose adjustments, particularly useful in pediatric or elderly patients who may require dose modifications.

Dosages for Adults and Adolescents:
For major depressive disorder and generalized anxiety disorder in adults, the initial recommended dose is 10 mg once daily, which may be increased to a maximum of 20 mg once daily after at least one week, based on clinical response and tolerability. Maintenance doses typically range from 10 to 20 mg daily. For adolescents aged 12 years and older with major depressive disorder, dosing starts at 10 mg once daily, with the possibility of increasing to 20 mg daily after a minimum of three weeks, with similar maintenance dosing. The maximum dose is 20 mg daily. Treatment duration in acute episodes may extend several months or longer to prevent relapse, with periodic reassessment.

Specific Patient Populations:
In geriatric patients, a starting dose of 10 mg daily is recommended for depression, reflecting altered pharmacodynamics and increased sensitivity. Dosage adjustments may be required in patients with hepatic or renal impairment due to decreased metabolism and clearance, warranting careful monitoring. Lexapro is contraindicated in children under 12 years old. Use in pregnancy requires risk-benefit assessment, with monitoring owing to potential neonatal complications. Caution is urged in patients with low sodium levels, seizure disorders, cardiac disease, and bipolar disorder.

The availability of multiple dosage forms and strengths allows for individualized therapy based on age, clinical condition, and tolerability, enhancing treatment adherence and efficacy.

Mechanism Of Action

Escitalopram, the active S-enantiomer of citalopram, exerts its therapeutic effects primarily through selective inhibition of the serotonin transporter (SERT) on presynaptic neuronal membranes. By blocking SERT, escitalopram effectively prevents the reuptake of serotonin (5-hydroxytryptamine, 5-HT) into presynaptic neurons, elevating extracellular serotonin concentrations within the synaptic cleft. This increase in synaptic serotonin availability enhances serotonergic neurotransmission, which is implicated in mood regulation and anxiety control.

At the molecular level, escitalopram binds with high affinity and selectivity to SERT compared to other neurotransmitter transporters, such as the norepinephrine or dopamine transporters. This selectivity reduces off-target effects and contributes to an improved side effect profile relative to less selective antidepressants. The augmented serotonergic signaling subsequently modulates postsynaptic 5-HT receptor function, leading to downstream effects on neuronal plasticity and gene expression that are believed to underlie the antidepressant and anxiolytic effects observed clinically.

Comparative research indicates escitalopram’s S-enantiomer possesses greater potency and efficacy than the racemic citalopram mixture, which also contains the less active R-enantiomer. Clinical studies demonstrate that escitalopram provides robust symptom relief with improved tolerability. Furthermore, escitalopram's ability to modulate 5-HT1A autoreceptors over time leads to a desensitization process, enhancing serotonergic neurotransmission chronically and correlating with the delayed onset of therapeutic effects, often observed over 4 to 6 weeks.

Emerging evidence suggests escitalopram may also influence other molecular pathways, including neurotrophic factors such as brain-derived neurotrophic factor (BDNF), contributing to neurogenesis and synaptic remodeling. These neuroplastic changes are postulated to reinforce and sustain mood improvement beyond acute serotonin reuptake inhibition. Overall, escitalopram's mechanism balances high serotonin selectivity with favorable pharmacodynamics, substantiating its use in major depressive disorder and generalized anxiety disorder treatment.

Pharmacological Actions

Selective inhibition of serotonin reuptake via high-affinity binding to the presynaptic serotonin transporter.
Enhancement of serotonergic neurotransmission within the central nervous system.
Modulation and desensitization of postsynaptic and autoreceptor 5-HT receptors over chronic administration.
Minimal effects on norepinephrine and dopamine reuptake, resulting in a more favorable side effect profile.
Promotion of neuroplasticity and neurogenesis through upregulation of neurotrophic factors such as BDNF.
Anxiolytic and antidepressant effects via restoration of serotonergic balance in mood-regulating brain regions.
Reduction of symptoms associated with major depressive disorder, generalized anxiety disorder, and related conditions.
Demonstration of high selectivity and potency compared to racemic citalopram formulation.
Long elimination half-life supporting once-daily dosing and stable plasma concentrations.
Minimal interaction with other neurotransmitter systems, reducing risks of cognitive impairment or sedation.
Improvement in serotonergic synapse activity contributing to enhanced mood and decreased anxiety symptoms.
Exhibits reversible effects on serotonin transport, allowing for gradual withdrawal tapering and minimized discontinuation symptoms.
Acts primarily on central nervous system with limited peripheral adverse pharmacologic activities.
Demonstrated efficacy in both acute and maintenance phases of depressive and anxiety disorders.

Therapeutic Or Clinical Uses

Acute and maintenance treatment of major depressive disorder in adults and adolescents (12 years and older).
Treatment of generalized anxiety disorder in adult patients.
Management of anxiety symptoms associated with depression.
Off-label use for anxiety spectrum disorders under clinical discretion.
Potential use in treatment-resistant depression, particularly where selective serotonin enhancement is desired.
Adjunct therapy in certain mood disorders to reduce depressive and anxious symptomatology.
Improvement of overall quality of life and functional outcomes in mood and anxiety disorder patients.
Therapeutic benefits documented with once-daily oral dosing regimen enhancing compliance.
Useful in patients requiring medications with relatively fewer side effects and minimal sedation.
Treatment option for patients intolerant to other antidepressant classes due to improved tolerability.
May reduce recurrence rate of depressive episodes when used as maintenance therapy.
Demonstrated efficacy across diverse ethnicities and patient populations in randomized controlled trials.
Indicated for use in populations with comorbid anxiety and depression symptoms.
Potential positive influence on cognition secondary to mood improvement in depressive disorders.
Extensively studied across multiple clinical trials with endorsement by psychiatric guidelines.

Side Or Adverse Effects

Common adverse effects include dizziness, drowsiness, fatigue, and weakness.
Experience of anxiety or agitation, sometimes transient during treatment initiation.
Gastrointestinal disturbances such as nausea and constipation.
Increased sweating (hyperhidrosis) including night sweats.
Dry mouth, increased thirst, and yawning episodes.
Sexual dysfunction including decreased libido, impotence, delayed ejaculation, and anorgasmia.
Sleep disturbances, most notably insomnia.
Nosebleeds and abnormal menstrual bleeding patterns.
Uncommon but serious side effects include signs of allergic reactions such as rash or hives.
Potential for serotonin syndrome manifested by agitation, hallucinations, fever, muscle stiffness, and coordination difficulties.
Rare cases of severe nervous system reactions including muscle rigidity, high fever, tremors, and cardiovascular instability.
Hyponatremia symptoms like headache, confusion, severe weakness, and slurred speech, particularly in elderly or at-risk individuals.
Behavioral changes such as mood swings, suicidal ideation especially in young adults and adolescents.
Blurred vision, tunnel vision, or ocular pain reported in rare instances.
Withdrawal symptoms may occur on abrupt discontinuation, including flu-like symptoms, irritability, and sensory disturbances.

Precautions

Use cautiously in patients with a history of bipolar disorder due to risk of inducing mania.
Patients with seizure disorders require monitoring as escitalopram may lower seizure threshold.
Monitor serum sodium levels in elderly or those predisposed to hyponatremia.
Evaluate liver and kidney function prior to and during therapy in patients with hepatic or renal impairment.
Careful assessment of bleeding risk especially when co-administered with NSAIDs, anticoagulants, or antiplatelet agents.
Closely monitor for worsening depression, suicidal ideation, or behavioral changes particularly in children and young adults.
Avoid sudden discontinuation to prevent withdrawal symptoms; taper doses gradually under medical supervision.
Inform patients about potential sexual dysfunction and provide counseling or therapeutic options if needed.
Avoid use in combination with MAO inhibitors within 14 days before or after therapy to prevent serotonin syndrome.
Advise against alcohol consumption due to additive CNS effects.
Special caution during pregnancy and breastfeeding; evaluate benefits versus potential neonatal risks.
Adjust dosing or avoid in patients with severe cardiac disease or uncontrolled hypertension.
Recommend vigilance regarding drug interactions with CYP450 inhibitors or inducers affecting escitalopram metabolism.
Use in pediatric patients under 12 years is contraindicated.
Regularly assess growth and weight in pediatric patients receiving treatment.

Warnings

Concomitant use with pimozide or citalopram is contraindicated due to potential for serious interactions.
Do not initiate or use within 14 days of MAO inhibitor therapy to prevent life-threatening serotonin syndrome.
Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults during initial treatment phases.
Potential for serotonin syndrome when used with other serotonergic agents or drugs impairing serotonin metabolism.
Discontinue therapy under medical guidance to avoid abrupt withdrawal symptoms or rebound effects.
May cause sexual dysfunction impacting quality of life; discuss potential effects prior to treatment initiation.
Caution in patients with bleeding disorders or those receiving medications that increase bleeding risk.
Risk of hyponatremia especially in elderly and volume-depleted individuals; monitor sodium levels.
Use during late pregnancy may lead to neonatal complications including respiratory distress and persistent pulmonary hypertension.
Patients should avoid operating heavy machinery until effects on cognition and motor skills are established.
Monitor for emergence of mania or hypomania in predisposed patients.
Risk of eye disorders such as blurred or tunnel vision necessitates prompt evaluation.
May exacerbate conditions related to bipolar disorder if unrecognized.
Serious allergic reactions though rare require immediate medical attention.
Not approved for use in pediatric patients under 12 years of age.

Contraindication

Hypersensitivity to escitalopram, citalopram, or any component of the formulation.
Concurrent use with pimozide is strictly contraindicated.
Use within 14 days of monoamine oxidase inhibitors (MAOIs) administration, including isocarboxazid, phenelzine, selegiline, rasagiline, tranylcypromine, linezolid, or methylene blue injection.
Known history of serotonin syndrome or hypersensitivity reactions to SSRIs.
Pediatric patients younger than 12 years of age due to potential risk and lack of established safety.
Concomitant use with racemic citalopram to avoid overdose-related toxicity.
Use in combination with other drugs that strongly inhibit CYP2C19 or CYP3A4 without medical supervision.
Patients with a recent history of angle-closure glaucoma unless controlled.
Severe hepatic impairment without appropriate dosage adjustment.
Severe renal impairment when dose adjustments cannot be implemented.
Patients with uncontrolled bipolar disorder or untreated manic episodes.
Use in pregnancy without thorough risk-benefit assessment.
Use in patients taking triptans, fentanyl, lithium, tramadol, or other serotonergic agents without physician oversight.
Patients who have exhibited hypersensitivity reactions to selective serotonin reuptake inhibitors previously.
Individuals with active bleeding or coagulopathy without adequate monitoring.

Drug Interactions

Potentially fatal serotonin syndrome when combined with other serotonergic agents including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John’s Wort.
Increased risk of bleeding when used concomitantly with anticoagulants (e.g., warfarin), antiplatelet drugs, or nonsteroidal anti-inflammatory drugs (NSAIDs).
Interaction with monoamine oxidase inhibitors (MAOIs) including isocarboxazid, phenelzine, selegiline, rasagiline, linezolid, and methylene blue leads to serious adverse effects; requires 14-day washout period before or after escitalopram therapy.
CYP2C19 inhibitors (e.g., omeprazole, fluconazole) may increase plasma levels of escitalopram, raising risk of toxicity.
CYP3A4 inducers (e.g., carbamazepine, phenytoin) may reduce escitalopram effectiveness by enhancing metabolism.
Sedative effects may be potentiated when combined with central nervous system depressants such as opioids, benzodiazepines, muscle relaxants, or alcohol.
Use with drugs prolonging QT interval should be cautious due to additive cardiotoxicity risk.
Concomitant use with pimozide may cause serious cardiac arrhythmias and is contraindicated.
Caution with stimulant medications and herbal supplements that affect serotonergic neurotransmission.
Avoid simultaneous use with linezolid or intravenous methylene blue due to risk of serotonin syndrome.
Interaction with tramadol may increase seizure risk and serotonin syndrome.
Co-administration with St. John’s Wort may unpredictably alter escitalopram plasma concentrations and increase adverse effects.
Anti-seizure medications may alter escitalopram metabolism; dose adjustments might be necessary.
Patients on anticoagulants require close monitoring of INR or bleeding parameters when starting or stopping escitalopram.
Interaction with NSAIDs heightens potential for gastrointestinal bleeding and should be monitored.

Preparations Of The Drug

Oral Tablets: available in strengths of 5 mg, 10 mg, and 20 mg; contain escitalopram oxalate as the active ingredient.
Oral Solution: contains escitalopram oxalate at 1 mg/mL concentration; inactive ingredients include sorbitol, purified water, citric acid, sodium citrate, malic acid, glycerin, propylene glycol, methylparaben, propylparaben, and natural peppermint flavor (note: currently not marketed).
Tablet excipients include talc, croscarmellose sodium, microcrystalline cellulose/colloidal silicon dioxide, and magnesium stearate; film coating contains hypromellose, titanium dioxide, and polyethylene glycol.
Supplied in bottles with secure closures to maintain stability and prevent contamination.
Storage instructions recommend maintaining temperature between 68°F to 77°F (20°C to 25°C), allowing excursions between 59°F and 86°F (15°C to 30°C).
Shelf-life specified by manufacturer with appropriate expiration dating.
Packaged in various unit doses to facilitate accurate dispensing and dosing adherence.
Manufactured by Allergan USA, Inc., Madison, NJ 07940.